Campus alert status is yellow: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Celia A Schiffer






UMassMed Faculty Page


Title: Co-evolved Protease Substrate Cleavage Site Mutations Enhance Protease Inhibitor Resistance. UMMS08-59; Patent Pending.  

  • This new invention predicates on the finding that drug resistance in HIV arises from evolution of HIV proteases and it’s associated substrates, and discloses mutation patterns of both proteases and substrates that can be used to predict the efficacy of particular therapy in HIV patients. Understanding these mutational combinations will greatly change the approach to optimizing a patient-centered approach to managing HIV therapy. 

Title: HIV-1 Protease Inhibitors: Part 6. UMMS08-41.

  • This invention provides new therapeutic agents to treat HIV using protease inhibitors that are less prone to resistance stemming from drug resistant mutations. Using computational and organic chemistry techniques, the inventors designed these new molecules by carefully considering nature of the HIV protease and it’s ability to detect substrates. This invention contains several sets of HIV protease inhibitors and unique drug combinations that have not yet been previously tested. 


Innovation TopicsSmall MoleculesAIDsHIVInfectious Disease